GT Biopharma (NASDAQ:GTBP) Stock Price Down 3.3% – Here’s What Happened

GT Biopharma, Inc. (NASDAQ:GTBP)’s share price traded down 3.3% during trading on Thursday . The stock traded as low as $0.38 and last traded at $0.3895. 594,684 shares were traded during trading, a decline of 21% from the average session volume of 754,989 shares. The stock had previously closed at $0.4027.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of GT Biopharma in a research report on Friday, April 10th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has an average rating of “Sell”.

GT Biopharma Stock Performance

The firm has a 50-day moving average price of $0.41 and a 200-day moving average price of $0.58. The stock has a market cap of $13.87 million, a PE ratio of -0.06 and a beta of 0.64.

Hedge Funds Weigh In On GT Biopharma

An institutional investor recently bought a new position in GT Biopharma stock. SeaCrest Wealth Management LLC acquired a new position in GT Biopharma, Inc. (NASDAQ:GTBP) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 50,000 shares of the company’s stock, valued at approximately $37,000. SeaCrest Wealth Management LLC owned approximately 0.47% of GT Biopharma as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 8.15% of the company’s stock.

GT Biopharma Company Profile

GT Biopharma, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel immuno-oncology therapies utilizing its proprietary Tri-specific NK cell engager (TriKE) platform. This technology is designed to harness and enhance the body’s natural killer (NK) cells by simultaneously binding tumor antigens and interleukin-15 (IL-15), stimulating NK cell proliferation and targeted cytotoxicity. By focusing on NK cell engagement rather than T-cell activation, the company aims to offer therapies with potentially improved safety profiles and reduced immune-related adverse events.

The company’s lead candidate, GTB-3550, is currently in clinical trials for hematologic malignancies such as acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL) and myelodysplastic syndromes (MDS).